PDCD1 and neoplasm: Slightly lower levels of T-cell immune inhibitory receptors PD-1, LAG-3, and TIM-3, proliferation, and GZMB were also observed in this patient’s tumor supporting reduced T-cell exhaustion/dysfunction during treatment.